IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS - Takeaways - MDSpire

IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS

  • By

  • Veronica Buia

  • Cecilia Catellani

  • Stefania Croci

  • Beatrice Righi

  • Daria Morini

  • Angela Immacolata Falbo

  • Alessia Nicoli

  • Alessandro De Fanti

  • Lucia Belloni

  • Lorenzo Aguzzoli

  • Maria Teresa Villani

  • Chiara Sartori

  • Maria Elisabeth Street

  • June 5, 2026

  • 0 min

Share

  • 1

    Polycystic ovary syndrome (PCOS) affects 5%-18% of women of reproductive age and is characterized by chronic inflammation and insulin resistance.

  • 2

    In a study of 70 PCOS patients and 70 controls, IGF-II and IGFBP-4 levels were lower in PCOS, while IGFBP-6 and IGFBP-7 levels were increased.

  • 3

    HMGB1 levels were found to be increased in the follicular fluid of PCOS patients, indicating a link to inflammation and insulin sensitivity.

  • 4

    Stratification by BMI showed that under/normal weight PCOS women had specific alterations in IGF-II and IGFBP levels compared to controls.

  • 5

    The study suggests that changes in IGF system proteins in PCOS may contribute to reduced follicular development and increased inflammatory status.

Original Source(s)

IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS

  • by Veronica Buia, Cecilia Catellani, Stefania Croci, Beatrice Righi, Daria Morini, Angela Immacolata Falbo, Alessia Nicoli, Alessandro De Fanti, Lucia Belloni, Lorenzo Aguzzoli, Maria Teresa Villani, Chiara Sartori, Maria Elisabeth Street

  • June 5, 2026

Related Content

Optimal Dietary Patterns for Lower Weight Gain and Risk of Obesity Surrounding Menopause

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Case Report: rapid progressive puberty in siblings with MC4R p. Arg165Gln: longitudinal follow-up and gonadotropin-releasing hormone agonist treatment